Lipid-Based Nanoparticles to Treat Cancer Tumors

Baltimore-based Champions Biotechnology has opted to license Irinophore C, from the BC Cancer Agency (‘BCCA’) in British Columbia, Canada.

Irinophore C is a nanoparticle based on lipid  created by incorporating the irinotecan payload into its center. The compound is under development and will enter phase I lab testing as an individual agent in patients who have solid tumors in the advanced stage in the fourth quarter of 2011. The company tested Irinophore C with its Tumorgraft translational technology platform. The results showed that Irinophore C was safe and could be used on multiple tumor types.

The Company has also declared that it will not take forward the three compounds for which it entered into licensing deals. After reviewing the Tumorgraft test results on the compounds the scientific advisory committee has advised that further resources should not be invested in developing these compounds. The company will also not carry forward the licensing of more compounds, but will focus on developing the Tumorgraft technology platform. The Company will however increase its Translational Oncology Solutions business.

Source http://www.championsbiotechnology.com/